This site is intended for healthcare professionals

2625 pages added, reviewed or updated during the last month (last updated: 15/4/2021)

2625 pages added, reviewed or updated during the last month (last updated: 15/4/2021)


Medical search

dornase alfa

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

  • dornase alfa is a genetically engineered version of human DNAase
  • the sputum of patients with cystic fibrosis (CF) contains large amounts of DNA - the viscoelastic property of sputum in CF patients is due to the inherent viscosity of DNA, and the mucus glycoproteins
  • nebulised dornase alfa is a well tolerated and safe treatment option in CF - dornase alfa reduces the viscosity of CF sputum by decreasing DNA strand size
  • there is evidence of medium-term improvement in lung function

NICE state that (1):

  • a mucoactive agent should be offered to people with cystic fibrosis who have clinical evidence of lung disease

  • rhDNase (dornase alfa; recombinant human deoxyribonuclease) should be offered as the first choice of mucoactive agent

  • if clinical evaluation or lung function testing indicates an inadequate response to rhDNase, consider both rhDNase and hypertonic sodium chloride or hypertonic sodium chloride alone

  • consider mannitol dry powder for inhalation for children and young people who cannot use rhDNase and hypertonic sodium chloride because of ineligibility, intolerance or inadequate response.

Reference:

Last reviewed 01/2018

Links: